Currently, adjuvants in clinical-stage TB vaccines include TLR-9 agonist CpG-ODN1a, liposomal formulations and emulsions (such as AS01, CAF01, and GLA-SE), and other adjuvants such as IC31. Here, TLR9 is linked to tuberculosis.